Condition: Waldenstrom Macroglobulinemia · Lymphoplasmacytic Lymphoma · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study is to find out if the combination of pirtobrutinib, venetoclax, and rituximab is an effective treatment for participants with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)
This description comes directly from the study's public registry record.
M. Lia Palomba, MD · 646-608-3711 · Palombam@MSKCC.ORG
Jennifer Lue, MD · 646-608-4160 · luej@mskcc.org
Always discuss trial participation with your own doctor first.
| Dana Farber Cancer Institute (Data Collection and Specimen Analysis) | Boston, Massachusetts, United States | Recruiting |
| Beth Israel Deaconess Medical Center (Data Collection Only) | Boston, Massachusetts, United States | Recruiting |
| Memorial Sloan Kettering Basking Ridge | Basking Ridge, New Jersey, United States | Recruiting |
| Memoral Sloan Kettering Monmouth | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Suffolk - Commack | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau | Uniondale, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07231952